FDA Approved: TRODELVY — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TRODELVY (sacituzumab govitecan) filed by Gilead Sciences, resulting in labeling changes for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

SUPPL AP for TRODELVY (SACITUZUMAB GOVITECAN)